Peter Friedli

Peter Friedli discloses dealings in Osiris Therapeutics, Inc. to SEC (Form 4). In total, 26 filings cover trades dated from 5 February 2007 to 17 April 2019.

In open-market terms, that means 4 purchases worth €19.3M on one side and 2 sales worth €373k on the other. The net balance comes to €18.9M on the buying side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 7 share grants and 2 option exercises.

Half of the purchases are above €4.0M and half below.

On 17 April 2019 came the latest disclosure, a transaction for €171.6M in Osiris Therapeutics, Inc. The latest purchase dates back some time: it was published 6,553 days ago, on 14 November 2008. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.